PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
M Cunningham, MJ Schiewer - Cancer Research, 2024 - AACR
PARP is a nuclear enzyme with a major function in the DNA damage response. PARP
inhibitors (PARPi) have been developed for treating tumors harboring homologous …
inhibitors (PARPi) have been developed for treating tumors harboring homologous …
[HTML][HTML] Derivation of human primary prostate epithelial cell lines by differentially targeting the CDKN2A locus along with expression of hTERT
JS Wasserman, H Fowle, R Hashmi, D Atar… - Research …, 2024 - ncbi.nlm.nih.gov
Prostate cancer (PCa) is the most common cancer diagnosed in men worldwide and the
second leading cause of cancer-related deaths in US males in 2022. Prostate cancer also …
second leading cause of cancer-related deaths in US males in 2022. Prostate cancer also …
How clinically relevant are prostate cancer cell lines? A comprehensive characterisation and multiomics comparison
Z Ahmed, W Mosabbir, D Tandon, SP Pereira… - bioRxiv, 2024 - biorxiv.org
Cell line experiments arguably remain the most used tool in preclinical cancer research,
despite their limitations. With almost 95% drugs entering human trials failing, and up to 90 …
despite their limitations. With almost 95% drugs entering human trials failing, and up to 90 …
[图书][B] Characterization of Immortalized Human Prostate Epithelial Cells
R Hashmi - 2023 - search.proquest.com
Prostate cancer (PCa) accounts for an estimated 20% of new cancer cases and 10% of
deaths in just US males in 2020. Despite this prevalence, the molecular basis of its …
deaths in just US males in 2020. Despite this prevalence, the molecular basis of its …